Bridging the Gap between Preclinical and Clinical Studies Using Pharmacokinetic-Pharmacodynamic Modeling: An Analysis of GDC-0973, a MEK InhibitorWONG, Harvey; VERNILLET, Laurent; HOEFLICH, Klaus P et al.Clinical cancer research (Print). 2012, Vol 18, Num 11, pp 3090-3099, issn 1078-0432, 10 p.Article

Significant Species Difference in Amide Hydrolysis of GDC-0834, a Novel Potent and Selective Bruton's Tyrosine Kinase InhibitorLICHUAN LIU; HALLADAY, Jason S; KUEBLER, Peter et al.Drug metabolism and disposition. 2011, Vol 39, Num 10, pp 1840-1849, issn 0090-9556, 10 p.Article

Absorption, Distribution, Metabolism, and Excretion of [¹⁴C]GDC-0449 (Vismodegib), an Orally Active Hedgehog Pathway Inhibitor, in Rats and Dogs: A Unique Metabolic Pathway via Pyridine Ring OpeningQIN YUE; CHEN, Yung-Hsiang; CYRUS KHOJASTEH, S et al.Drug metabolism and disposition. 2011, Vol 39, Num 6, pp 952-965, issn 0090-9556, 14 p.Article

Pharmacokinetic-Pharmacodynamic Analysis of Vismodegib in Preclinical Models of Mutational and Ligand-Dependent Hedgehog Pathway ActivationWONG, Harvey; ALICKE, Bruno; WEST, Kristina A et al.Clinical cancer research (Print). 2011, Vol 17, Num 14, pp 4682-4692, issn 1078-0432, 11 p.Article

N-in-1 Dosing Pharmacokinetics in Drug Discovery : Experience, Theoretical and Practical ConsiderationsKAN HE; MINGXIN QIAN; HANG ZENG et al.Journal of pharmaceutical sciences. 2008, Vol 97, Num 7, pp 2568-2580, issn 0022-3549, 13 p.Article

Interplay of Dissolution, Solubility, and Nonsink Permeation Determines the Oral Absorption of the Hedgehog Pathway Inhibitor GDC-0449 in Dogs: An Investigation Using Preclinical Studies and Physiologically Based Pharmacokinetic ModelingWONG, Harvey; THEIL, Frank-Peter; YUZHONG DENG et al.Drug metabolism and disposition. 2010, Vol 38, Num 7, pp 1029-1038, issn 0090-9556, 10 p.Article

In Vitro Intrinsic Clearance-Based Optimization of N³-Phenylpyrazinones as Corticotropin-Releasing Factor-1 (CRF₁) Receptor AntagonistsHARTZ, Richard A; AHUJA, Vijay T; LELAS, Snjezana et al.Journal of medicinal chemistry (Print). 2009, Vol 52, Num 14, pp 4161-4172, issn 0022-2623, 12 p.Article

Kinetics of valproic acid glucuronidation : Evidence for in vivo autoactivationWONG, Harvey; TONG, Vincent; RIGGS, K. Wayne et al.Drug metabolism and disposition. 2007, Vol 35, Num 8, pp 1380-1386, issn 0090-9556, 7 p.Article

Design, synthesis, and biological evaluation of 1,2,3,7-tetrahydro-6H-purin-6-one and 3,7-dihydro-1h-purine-2,6-dione derivatives as corticotropin-releasing factor₁ receptor antagonistsHARTZ, Richard A; NANDA, Kausik K; ZACZEK, Robert et al.Journal of medicinal chemistry (Print). 2004, Vol 47, Num 19, pp 4741-4754, issn 0022-2623, 14 p.Article

Comparative Biotransformation of Pyrazinone-Containing Corticotropin-Releasing Factor Receptor-1 Antagonists: Minimizing the Reactive Metabolite FormationXIAOLIANG ZHUO; HARTZ, Richard A; BRONSON, Joanne J et al.Drug metabolism and disposition. 2010, Vol 38, Num 1, pp 5-15, issn 0090-9556, 11 p.Article

Synthesis, Structure—Activity Relationships, and In Vivo Evaluation of N³-Phenylpyrazinones as Novel Corticotropin-Releasing Factor-1 (CRF₁) Receptor AntagonistsHARTZ, Richard A; AHUJA, Vijay T; HOBBS, Frank W et al.Journal of medicinal chemistry (Print). 2009, Vol 52, Num 14, pp 4173-4191, issn 0022-2623, 19 p.Article

Synthesis, structure-activity relationships, and in vivo properties of 3,4-dihydro-1H-pyrido[2,3-b]pyrazin-2-ones as corticotropin-releasing factor-1 receptor antagonistsDZIERBA, Carolyn D; TAKVORIAN, Amy G; MCELROY, John F et al.Journal of medicinal chemistry (Print). 2004, Vol 47, Num 23, pp 5783-5790, issn 0022-2623, 8 p.Article

Histologic changes of nonbiodegradable and biodegradable biomaterials used to repair right ventricular heart defects in ratsOZAWA, Tsukasa; MICKLE, Donald A. G; WEISEL, Richard D et al.Journal of thoracic and cardiovascular surgery. 2002, Vol 124, Num 6, pp 1157-1164, issn 0022-5223, 8 p.Article

Antitumor Activity of Targeted and Cytotoxic Agents in Murine Subcutaneous Tumor Models Correlates with Clinical ResponseWONG, Harvey; CHOO, Edna F; GOULD, Stephen E et al.Clinical cancer research (Print). 2012, Vol 18, Num 14, pp 3846-3855, issn 1078-0432, 10 p.Article

Influence of the Compound Selection Process on the Performance of Human Clearance Prediction MethodsWONG, Harvey; LEWIN-KOH, Sock-Cheng; THEIL, Frank-Peter et al.Journal of pharmaceutical sciences. 2012, Vol 101, Num 2, pp 509-515, issn 0022-3549, 7 p.Article

6-Hydroxybuspirone is a major active metabolite of buspirone : Assessment of pharmacokinetics and 5-hydroxytryptamine_1A receptor occupancy in ratsWONG, Harvey; DOCKENS, Randy C; PAJOR, Lori et al.Drug metabolism and disposition. 2007, Vol 35, Num 8, pp 1387-1392, issn 0090-9556, 6 p.Article

Synthesis and evaluation of 2-anilino-3-phenylsulfonyl-6-methylpyridines as corticotropin-releasing factor₁ receptor ligandsHARTZ, Richard A; ARVANITIS, Argyrios G; ARNOLD, Charles et al.Bioorganic & medicinal chemistry letters (Print). 2006, Vol 16, Num 4, pp 934-937, issn 0960-894X, 4 p.Article

The chimpanzee (Pan troglodytes) as a pharmacokinetic model for selection of drug candidates: Model characterization and applicationWONG, Harvey; GROSSMAN, Scott J; BAI, Stephen A et al.Drug metabolism and disposition. 2004, Vol 32, Num 12, pp 1359-1369, issn 0090-9556, 11 p.Article

Clearance and disposition of indometacin in chronically instrumented fetal lambs following a 3-day continuous intravenous infusionKRISHNA, Rajesh; RIGGS, K. Wayne; KWAN, Eddie et al.Journal of pharmacy and pharmacology. 2002, Vol 54, Num 6, pp 801-808, issn 0022-3573Article

Enzyme-inducing Anticonvulsants Increase Plasma Clearance of Dexmedetomidine: A Pharmacokinetic and Pharmacodynamic StudyFLEXMAN, Alana M; WONG, Harvey; RIGGS, K. Wayne et al.Anesthesiology (Philadelphia). 2014, Vol 120, Num 5, pp 1118-1125, issn 0003-3022, 8 p.Article

Determination of unbound vismodegib (GDC-0449) concentration in human plasma using rapid equilibrium dialysis followed by solid phase extraction and high-performance liquid chromatography coupled to mass spectrometryYUZHONG DENG; WONG, Harvey; DEAN, Brian et al.Journal of chromatography. B. 2011, Vol 879, Num 22, pp 2119-2126, issn 1570-0232, 8 p.Article

Orally Bioavailable Antagonists of Inhibitor of Apoptosis Proteins Based on an Azabicyclooctane ScaffoldCOHEN, Frederick; ALICKE, Bruno; VUCIC, Domagoj et al.Journal of medicinal chemistry (Print). 2009, Vol 52, Num 6, pp 1723-1730, issn 0022-2623, 8 p.Article

8-(4-Methoxyphenyl)pyrazolo[1,5-a]-1,3,5-triazines: Selective and Centrally Active Corticotropin-Releasing Factor Receptor-1 (CRF₁) AntagonistsGILLIGAN, Paul J; LIQI HE; MARSHALL, Anne et al.Journal of medicinal chemistry (Print). 2009, Vol 52, Num 9, pp 3073-3083, issn 0022-2623, 11 p.Article

Synthesis and Structure―Activity Relationships of 8-(Pyrid-3-yl)pyrazolo[1,5-a]-1,3,5-triazines: Potent, Orally Bioavailable Corticotropin Releasing Factor Receptor-1 (CRF₁) AntagonistsGILLIGAN, Paul J; CLARKE, Todd; KRAUSE, Carol et al.Journal of medicinal chemistry (Print). 2009, Vol 52, Num 9, pp 3084-3092, issn 0022-2623, 9 p.Article

N-phenylphenylglycines as novel corticotropin releasing factor receptor antagonistsMOLTENI, Valentina; PENZOTTI, Julie; GROSSMAN, Scott et al.Journal of medicinal chemistry (Print). 2004, Vol 47, Num 10, pp 2426-2429, issn 0022-2623, 4 p.Article